Should an off-label , permissive one-dose HPV vaccine schedule for use in routine and/or multi-age cohort (MAC) catch up strategies be recommended?

Population: Main population is pre-adolescent and adolescent girls (9-14 years old), but boys and older adults are also included.

Intervention: Single dose vaccination; bivalent (Cervarix and Cecolin), quadrivalent (Gardasil), and nonavalent vaccines (Gardasil 9).

Comparison(s): No vaccination

Outcome: Clinical outcomes: including, but not limited to invasive cervical, vaginal, vulval, anal, penile or head and neck cancer; cervical intraepithelial neoplasia (CIN) grade 3+; CIN2+; histological and cytological abnormalities; anogenital warts; high risk HPV infection (genotype-specific prevalence, incidence and/or persistence) Immunological outcome; seroconversion or seropositivity; geometric mean titers (GMT) of HPV antibodies